A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.

NCT Number	NCT07340424
Lead Sponsor	Xiaorong Sun
Conditions	Advanced Metastatic Triple-negative Breast Cancer (mTNBC)
Enrollment	15 participants
Start Date	2025-05-22
Primary Completion	2027-04 (estimated)
Study Completion	2029-05 (estimated)
Updated on ClinicalTrials.gov	2026-01-14